Home › NCT06726811

Droperidol and QTc Interval Changes in ED Patients

Low-Dose Droperidol and Its Association with QTc Interval Changes in Emergency Department Patients

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* ED patients ages 18 years or older in a cardiovascular-monitored bed who have both an ECG and a 2.5 mg dose of IV droperidol ordered by their treating physician will be eligible for inclusion.

Exclusion Criteria:

* Refusal to provide consent.
* Administration of droperidol before the first ECG is performed.
* Inability to complete the consent form and questionnaire due to clinical instability, severe pain, or disorientation as determined by a study physician.

About the study

Objectives To assess the association of low-dose Droperidol administration in the emergency department with changes in the QTc interval.

Hypothesis Our study is designed to test the null hypothesis that there will be no clinically significant change in QTc interval after administration of 2.5mg of IV Droperidol during an emergency department visit.

What is being tested

• Droperidol injection (drug)

Sponsor: CHRISTUS Health · Participants: 500 · Started: Oct 17, 2024

Contact the study team

• Aaron K Bartoe, DO, MS · Phone: (863) 532-8408

Official record on ClinicalTrials.gov — NCT06726811

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.